DVA vs SNY: fair value comparison
DaVita Inc. and Sanofi · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, DVA currently sits closer to the top of our discount ranking. SNY carries the stronger quality grade.
| DVA | SNY | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $180.68 | $42.95 |
| 12-month range | $111.19–$240.09 | $41.63–$47.40 |
| Sector rank | #39 of 113 Healthcare | #41 of 113 Healthcare |
| Quality grade | C | B |
| Leverage | Low | Low |
| Margin trend | Stable | Expanding |
| Revenue growth | Modest | Modest |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | — | Downtrend |
| DCF cross-check | Undervalued | Overvalued |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: DVA fair value analysis · SNY fair value analysis